- ►diabetesjournals.org MA Deeg, JB Buse, RB Goldberg, DM Kendall, AJ … - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This is a prospective, randomized, double-blind, multicenter,
parallel-group study. After a 4-week placebo washout period, patients randomized to PIO (n = 369)
were treated with 30 mg qd for 12 ... Cited by 36 - Related articles - BL Direct - All 5 versions
K Berneis, M Rizzo, C Stettler, B Chappuis … - Expert Opin. …, 2008 - informahealthcare.com Objective: To assess the effects of pioglitazone and rosiglitazone on fasting and postprandial
low-density lipoprotein (LDL) size and subclasses in patients with Type 2 diabetes. Research design
and methods: Nine Type 2 diabetic ... Cited by 10 - Related articles - BL Direct - All 6 versions
B Chappuis, M Braun, C Stettler, S Allemann, … - Diabetes/Metabolism … - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets. In
this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the ... Cited by 18 - Related articles - BL Direct - All 4 versions
- ►oxfordjournals.org DJ Betteridge, RA DeFronzo, RJ Chilton - European Heart Journal, 2008 - Eur Soc Cardiology The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) remains the
only completed cardiovascular (CV) outcomes study with a thiazolidinedione. It has provided
valuable information on the impact of pioglitazone on CV outcomes in a high-risk ... Cited by 12 - Related articles - BL Direct - All 10 versions
- ►diabetesjournals.org M Fernandez, C Triplitt, E Wajcberg, AA … - Diabetes Care, 2008 - Am Diabetes Assoc RESULTS—The decreases in A1C (∼9.0–7.0%) and fasting plasma glucose (∼190–128 mg/dl) were
equal in all groups. In the PIO group, glucose disposal increased from 3.1 to 4.7 mg · kg −1 ·
min −1 , and there was a greater ... Cited by 12 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org [PDF] E Erdmann, B Charbonnel, RG Wilcox, AM Skene, … - Diabetes Care, 2007 - Am Diabetes Assoc Page 1. Pioglitazone Use and Heart Failure in Patients with Type 2 Diabetes and Preexisting
Cardiovascular Disease: Data from the PROactive Study (PROactive 08) Erland Erdmann, MD,
FESC, FACC 1 ; Bernard Charbonnel, MD 2 ;Robert G Wilcox, MD ... Cited by 28 - Related articles - BL Direct - All 6 versions
G Derosa, A D'Angelo, PD Ragonesi, L … - Journal of Clinical …, 2006 - interscience.wiley.com Methods: This 12-month, multicentre, double-blind, randomized, controlled, parallel-group trial was
conducted at three study sites in Italy. We assessed patients with type 2 diabetes mellitus
(duration ≥6 months) and with ... Cited by 49 - Related articles - BL Direct - All 6 versions
P Berhanu, A Perez, S Yu - Diabetes, Obesity & Metabolism, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets. In
this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the ... Cited by 6 - Related articles - All 3 versions
- ►ahajournals.org R Wilcox, MG Bousser, DJ Betteridge, G Schernthaner, … - Stroke, 2007 - Am Heart Assoc Results— In patients with previous stroke (n=486 in the pioglitazone group and n=498 in the
placebo group), there was a trend of benefit with pioglitazone for the primary end point of
all-cause death, nonfatal ... Cited by 93 - Related articles - All 6 versions
IJ Dahabreh - Clinical Trials, 2008 - ctj.sagepub.com Background A meta-analysis of randomized controlled trials suggested that rosiglitazone, a drug used
for the treatment of diabetes, may be associated with an increased risk of cardiovascular adverse
events. Three large randomized ... Cited by 22 - Related articles - BL Direct - All 2 versions
